Neurofilament light chain predicts disease activity in relapsing-remitting MS by Varhaug, Kristin Nielsen et al.









Laurence A. Bindoff, MD,
PhD









Neurofilament light chain predicts disease
activity in relapsing-remitting MS
ABSTRACT
Objective: To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1
(CHI3L1) predict disease activity in relapsing-remitting MS (RRMS).
Methods: A cohort of 85 patients with RRMS were followed for 2 years (6 months without
disease-modifying treatment and 18 months with interferon-beta 1a [IFNB-1a]). Expanded Dis-
ability Status Scale was scored at baseline and every 6 months thereafter. MRI was performed
at baseline and monthly for 9 months and then at months 12 and 24. Serum samples were col-
lected at baseline and months 3, 6, 12, and 24. We analyzed the serum levels of NF-L using a sin-
gle-molecule array assay and CHI3L1 by ELISA and estimated the association with clinical and
MRI disease activity using mixed-effects models.
Results: NF-L levels were significantly higher in patients with new T1 gadolinium-enhancing le-
sions (37.3 pg/mL, interquartile range [IQR] 25.9–52.4) and new T2 lesions (37.3 pg/mL, IQR
25.1–48.5) compared with those without (28.0 pg/mL, IQR 21.9–36.4, b 5 1.258, p , 0.001
and 27.7 pg/mL, IQR 21.8–35.1, b 5 1.251, p , 0.001, respectively). NF-L levels were asso-
ciated with the presence of T1 gadolinium-enhanced lesions up to 2 months before (p , 0.001)
and 1 month after (p5 0.009) the time of biomarker measurement. NF-L levels fell after initiation
of IFNB-1a treatment (p , 0.001). Changes in CHI3L1 were not associated with clinical or MRI
disease activity or interferon-beta 1a treatment.
Conclusion: Serum NF-L could be a promising biomarker for subclinical MRI activity and treat-
ment response in RRMS. In clinically stable patients, serum NF-L may offer an alternative to
MRI monitoring for subclinical disease activity.
ClinicalTrials.gov identifier: NCT00360906. Neurol Neuroimmunol Neuroinflamm2018;5:e422; doi:
10.1212/NXI.0000000000000422
GLOSSARY
CHI3L1 5 chitinase 3-like 1; CI 5 confidence interval; CIS 5 clinically isolated syndrome; CUA 5 combined unique activity;
EDSS 5 Expanded Disability Status Scale; IFNB-1a 5 interferon-beta 1a; IQR 5 interquartile range; NF-L 5 neurofilament
light chain; OR 5 odds ratio; RRMS 5 relapsing-remitting MS; Simoa 5 single-molecule array; T1GdE 5 T1-weighted
gadolinium-enhanced.
MS is a chronic inflammatory disease of the CNS in which neuronal damage is present at an
early stage.1 Due to both unpredictable and heterogeneous disease course and treatment
response, biomarkers reflecting these processes are highly sought after.
Neurofilaments are neuron-specific cytoskeletal proteins that can be released following axonal
damage. Elevated levels of these proteins have, therefore, been interpreted as reflecting axonal
damage and neuronal death in MS,2 Alzheimer disease,3 fronto-temporal dementia,4 and motor
neuron diseases.5,6 InMS, the neurofilament light chain (NF-L) subunit is considered a potential
biomarker for disease activity in CSF.7 In addition, correlations have been found between NF-L
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and risk of conversion to MS after optic neu-
ritis8 and between NF-L and treatment
response with immunomodulatory drugs such
as fingolimod9,10 and natalizumab.11 However,
a biomarker should preferably be detectable in
blood and not in CSF, as lumbar puncture is
invasive and not appropriate for repetitive
sampling and long-time follow-up. Serum lev-
els of NF-L have been investigated in several
studies. Elevated NF-L levels have been found
in patients with clinically isolated syndrome
(CIS) and relapsing-remitting MS (RRMS)
and have been correlated with MRI measures
of disease severity and EDSS.12,13 However,
the methods for analyzing NF-L in serum have
varied, and a standardized assay is not yet es-
tablished. Thus, we wanted to evaluate the
potential of NF-L as a serum biomarker using
a single-molecule array (Simoa) assay, in the
follow-up of patients with RRMS, before and
during interferon-beta 1a (IFNB-1a) therapy.
We also included another biomarker chiti-
nase 3-like 1 (CHI3L1) also known as YKL
40. CHI3L1 is a member of the glycoside
hydrolase 18 chitinase family but lacks chitino-
lytic activity.14 It is upregulated in numerous
chronic inflammatory conditions and is ex-
pressed by several cells, including microglia,
macrophages, and astrocytes.14 In proteomic
studies,15,16 CHI3L1 has been identified as
a potential biomarker for MS, and CHI3L1
levels in CSF have been proposed as a prognos-
tic marker for conversion from CIS toMS.8,14,17
The aim of this study was to evaluate the
potential of NF-L and CHI3L1 as serum
biomarkers for clinical use in the follow-up
of patients with RRMS.
METHODS Study design and patients. The patient cohort
has its origin in a multicenter, randomized, double-blind, pla-
cebo-controlled trial to investigate the possible effect of v-3 fatty
acids on disease activity in MS (the OFAMS study) and has
previously been described in detail.18 Our study comprised 85
patients (92% of the originally included patients), all with RRMS
diagnosed according to the McDonald criteria. None were
receiving immunotherapy at inclusion. Patients were randomized
to supplement with high-dose v-3 fatty acids or placebo (corn
oil), and after 6 months, all patients were additionally treated with
subcutaneous 44 mg of IFNB-1a 3 times a week. Expanded
Disability Status Scale (EDSS) scoring was performed at baseline
and months 6, 12, and 24. Relapses were recorded throughout
the study period. T2-weighted and T1-weighted gadolinium-
enhanced (T1GdE) MRI scans were performed at baseline and
monthly thereafter for the first 9 months, then at months 12 and
24. MRI outcome measures were lesions defined as the presence
or absence of T1GdE lesions, new or enlarged T2-weighted le-
sions, or a combination of both (combined unique activity;
CUA).
Standard protocol approvals, registrations, and patient
consents. The study was approved by the Norwegian Regional
Committee for Medical and Health Research Ethics (No: REK-
no. 005.04), and written informed consent was obtained from
all patients (ClinicalTrails.gov NCT00360906).
Serum sampling and analysis. Measurement of serum NF-L
and CHI3L1 concentrations was performed on samples drawn
at baseline and follow-up at months 3, 6, 12, and 24. Serum
samples were stored at 280°C.
The concentration of NF-L was determined using a Simoa
assay (UmanDiagnostics, Umeå, Sweden).19,20 The concentration
of CHI3L1 in serum was measured using ELISA according to the
manufacturer’s protocol (R&D systems, Minneapolis, MN).
Intra- and inter-assay coefficients of variation were below 10%.
All serum analyses were performed blinded for patient ID and
clinical data.
Missing data. A total of 415 samples were analyzed in 85 pa-
tients. One sample (1.2%) at month 3, 3 at month 12 (3.5%),
and 6 at month 24 (7.1%) were missing for NF-L and
CHI3L1 measurements. In addition, another CH13L1 sample
was missing at month 24. MRI scans from 3 patients were
missing at month 3 (3.5%), from 1 patient at month 12 (1.2%)
and 3 patients at month 24 (3.5%). Four patients (4.7%) were
without EDSS scores at month 24.
Statistical analyses. We used mixed-effects models to account
for repeated measurements. Linear mixed-effects models with
random intercept were used to test for differences in log-
transformed levels of NF-L and CHI3L1 by age at inclusion,
sex, disease duration, relapses (new relapses or no new relapses),
progression in EDSS ($1 EDSS point or,1 EDSS point during
follow-up), IFNB-1a treatment (treatment or no treatment), and
MRI activity (new lesions or no new lesions). The regression
coefficients from these models were back-transformed to the
original scale. We tested whether a random slope improved the
model fit by comparing models with a random slope with models
without random slope using likelihood ratio tests. As this did not
significantly improve the model fit, we did not include a random
slope in the final models. We tested for interaction by a com-
paring model with an interaction term with a model without an






Mean age at inclusion, y (SD) 38.9 (8.4)
Mean age at symptom onset, y (SD) 33.0 (8.6)
Mean age at diagnosis, y (SD) 36.8 (9.9)
Mean disease duration, y (SD) 1.9 (3.1)
Mean EDSS (SD) 1.89 (0.8)
Median EDSS (interquartile range) 2 (1.5–2.5)
Mean no. of relapses the year before inclusion (SD) 1.6 (0.7)
EDSS 5 Expanded Disability Scale Status.
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interaction term using the likelihood ratios test. Furthermore, we
decomposed NF-L and CHI3L1 into mean levels for each patient
during follow-up and deviation from the mean at each time point
to estimate between-patient and within-patient effects. We used
random intercept logistic regression models to test whether mean
protein levels and deviation of the mean were independently
associated with MRI activity (new lesions or no new lesions).
Last, we created lead and lag variables to test whether NF-L and
CHI3L1 levels were correlated with MRI activity 1, 2, or 3
months before or after the measurement of these proteins. We
used the first 9 months of follow-up for these analyses, as MRIs
were conducted monthly in this period. As levels of the proteins
have been reported to be age dependent, all models were adjusted
for age. In addition, we adjusted all models for sex and follow-up
time. We tested model assumptions of the mixed-effects models
using diagnostic plots. All analyses were performed in Stata 14.1.,
while figures were made in R version 3.3.2. A p value of ,0.05
was considered statistically significant.
RESULTS Patients and MRI activity. Demographic
and clinical characteristics of the patients are summa-
rized in table 1. MRI disease activity, defined as pa-
tients with active scans, during the study period is
shown in table 2.
Association between demographic data and serum NF-L
and CHI3L1. Increased NF-L (p 5 0.001) but not
CHI3L1 levels were associated with age at inclusion.
Neither NF-L nor CHI3L1 levels were associated
with sex.
Association between clinical data and NF-L and CHI3L1.
Twenty-six patients experienced disability pro-
gression ($1 EDSS point) in the study period,
Table 2 MRI disease activity in patients with relapsing-remitting MS before
(baseline-month 6) and during (month 6 to month 24) interferon-beta
therapy
Time of examination
Proportion of patients with active scans,a n (%)
T1 gadolinium-enhancing
lesions




Baseline 45 (52.9) — —
3 mo 33 (38.8) 33 (38.8) 41 (48.2)
6 mo 34 (40.0) 32 (37.6) 39 (45.9)
12 mo 9 (10.6) 14 (16.5) 14 (16.5)
24 mo 15 (18) 19 (23) 19 (23)
a Active scans were defined as the presence of T1 gadolinium-enhancing lesions, new or
enlarged T2 lesions, or a combination of both.
Figure 1 Levels of neurofilament light chain (NF-L) associated with follow-up time (A) and MRI (B–D)
*p , 0.05.
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and there were a total of 42 relapses in 23 patients.
In multivariable linear mixed-effects models, nei-
ther NF-L nor CHI3L1 levels were significantly
associated with disease duration, relapses, or EDSS
progression. Nor was there any association
between NF-L or CHI3L1 levels and treatment
allocation in the original randomization between
v-3 fatty acids and placebo (the original OFAMS
study intervention). The NF-L levels were stable
during the first 6 months without treatment, but
fell following the initiation of IFNB-1a therapy,
and were lower at months 12 and 24 (p , 0.001,
figure 1A; table e-1 at Neurology.org/nn).
CHI3L1 levels were stable during the whole study
period, without any influence of IFNB-1a therapy
(figure 2A; table e-1).
Association between serum NF-L and CHI3L1 levels and
disease activity on MRI during follow-up. Higher NF-L
levels were associated with the development of new
T1 GdE lesions (p , 0.001), new or enlarged T2
lesions (p , 0.001), and CUA (p , 0.001) (figure 1,
B–D; table e-1) in multivariable analyses adjusting for
age, sex, and follow-up time. We examined whether
NF-L levels predicted new MRI-lesions during
follow-up on IFNB-1a and found no significant dif-
ferences in the associations before and after the ini-
tiation of treatment (p for interaction 5 0.26, 0.20,
and 0.35 for T1-GdE lesions, T2 lesions, and CUA,
respectively).
We also examined whether variation in NF-L lev-
els within and between patients was associated with
MRI activity and found that both were independently
associated with an increased risk of new lesions (table
e-2). A within-patient increase of 10 pg/mL in NF-L
levels was associated with increased odds of T1 GdE
lesions (odds ratio [OR]: 1.48, 95% confidence inter-
val [CI]: 1.15–1.90, p 5 0.002) and new T2 lesions
(OR 1.62, 95% CI 1.22–2.15, p 5 0.001).
Finally, we investigated the temporal relation-
ship between NF-L levels and MRI activity. Ele-
vated NF-L was associated with the occurrence of
T1 GdE lesions for up to 2 months before and 1
month after the time of biomarker measurement.
(p , 0.001 and p 5 0.009, respectively). Thus,
increased NF-L levels were present for a 3-month
period during the development of new lesions as
compared to patients without new T1 GdE lesions
Figure 2 Levels of chitinase 3-like 1 (CHI3L1) associated with follow-up time (A) and MRI (B–D)
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(figure 3). Levels of CHI3L1 showed no association
with MRI activity (figure 2, B–D; table e-1).
DISCUSSION We present a large cohort of RRMS in
which serum NF-L and CHI3L1 have been evaluated
by longitudinal sampling and multiple, clinical, and
radiologic assessments. Our most important findings
are the associations between serum NF-L and MRI
disease activity and the observed reduction in NF-L
levels after starting INFB-1a treatment. Due to the
longitudinal design of this study with repeated
measurements in each patient, we were able to assess
whether intraindividual change in NF-L levels were
associated with disease activity. As each individual
acts as his/her own control in these analyses, they may
be less prone to confounding compared with analyses
on between-individual changes. We observed that
both within and between variation were indepen-
dently associated with disease activity, adding weight
to the evidence linking serum NF-L levels to disease
activity.
Our results are similar to those from a study of na-
talizumab, where CSF NF-L levels decreased to the
same level as the healthy controls after 6 or 12 months
of treatment,11 and to studies looking at CSF NF-L
levels and fingolimod treatment.9,10 Our results are
also in accordance with the lower levels of CSF NF-
L in patients treated with mitoxantrone and rituxi-
mab. This last study looked, however, at patients with
progressive MS21; thus, the results are not directly
comparable with ours. Based on our findings, we
suggest that NF-L can be regarded as both a bio-
marker for disease activity and one that reflects the
treatment response. NF-L levels are known to be age
dependent; thus, the correlation between age and
NF-L is not surprising.
No correlation between serum CHI3L1 levels and
any clinical or radiologic feature was identified. Fur-
thermore, as has been reported previously,22 we found
no correlation between age and CHI3L1 levels. Our
results showing no significant association with either
MRI activity or EDSS score are supported by a recent
study that also found no significant differences in
CHI3L1 levels and disease activity.23 Indeed, this
study23 suggested that CHI3L1 may reflect the
response to IFNB-1a treatment in patients with
RRMS. Our study did not support this conclusion.
While we found no association between CHI3L1
and disease activity, levels in CSF have been found to
correlate with both GdE lesions and T2 lesions.14
This difference could reflect the fact that CSF
CHI3L1 is mainly brain derived14 and unable to cross
the blood-brain barrier sufficiently to give correlating
levels in serum. Earlier studies have shown that sig-
nificant levels of CSF CHI3L1 in patients with CIS
were not reproducible in serum.17 This probably re-
flects the finding that the serum concentration of
CHI3L1 is eight-fold lower than that in CSF15 and
demands greater sensitivity of measurement. Our
study confirms that CHI3L1 is not a reliable serum
Figure 3 Relationship between new T1 gadolinium-enhanced lesions and time of biomarker measurement
*p , 0.05; **p , 0.005.
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biomarker, despite being a potentially useful CSF bio-
marker.22 The finding of higher plasma concentra-
tions of CHI3L1 in progressive MS than RRMS24
may reflect the presence of other pathogenic pathways
than inflammation and this too could indicate that
CHI3L1 may not be useful as a prognostic marker for
RRMS or treatment response.
Our study has some limitations. First, the MRI
scans in our study were conducted more frequently
compared with what is done in clinical practice. This
may affect the generalizability of our results. Further-
more, the limited follow-up in our study may have
affected the power to detect associations between
NF-L and clinical outcomes. While most of the pa-
tients in our study experienced new lesions during
follow-up, only a proportion of the patients experi-
enced relapses or EDSS progression.
Our results indicate that serum NF-L may
become a biomarker for the analysis of subclinical
MRI activity and treatment response in RRMS.
Although the ratio between blood and CSF NF-L
levels is between 1/30 and 1/70,3 measurement of
NF-L in serum appears sensitive enough to be taken
into clinical use. This is in line with recent findings
in which NF-L in serum and CSF are highly corre-
lated.25 Our findings also suggest that NF-L not only
reflects disease activity but also indicates serum NF-
L as a promising biomarker in monitoring treatment
response. This is also supported by recent studies in
which serum NF-L was found to be a sensitive and
clinically useful biomarker to monitor tissue damage
and effects of therapies in MS.20,25 According to our
data, rising NF-L levels, with or without clinical
symptoms, may act as a trigger for MRI scanning.
Therefore, patients with stable clinical course and
stable NF-L levels may be spared unnecessary, and
costly, MRI scans. This needs to be confirmed in
larger prospective patient populations.
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